III

Annovis Bio Showcases Promising Progress in Novel Drug Development at the 2023 Clinical Trials on Alzheimer's Disease Conference

Retrieved on: 
Tuesday, October 24, 2023
Biotechnology, Neurology, Health, Pharmaceutical, Clinical Trials, FDA, AD, PD, NYSE, Bio, III, II, Human, Axonal transport, Neuroprotection, Mutation, Inflammation, Research, Protein, Clinical trial, Mouse, Parkinson's disease, Animal, New Drug Application, Brain, Buntanetap, NDA, Movement, Interim analysis, Neurotoxicity, Cognition, Pharmaceutical industry, Vaccine, Dietary supplement, Alzheimer's disease, Disease

Annovis Bio, Inc. (NYSE: ANVS), a late-stage clinical drug platform company developing transformative therapies to treat neurodegenerative diseases, including Alzheimer’s Disease (AD) and Parkinson’s Disease (PD), is presenting two posters at the Clinical Trials on Alzheimer's Disease (CTAD) 2023 annual conference held in Boston, Massachusetts, from October 24-27.

Key Points: 
  • Annovis Bio, Inc. (NYSE: ANVS), a late-stage clinical drug platform company developing transformative therapies to treat neurodegenerative diseases, including Alzheimer’s Disease (AD) and Parkinson’s Disease (PD), is presenting two posters at the Clinical Trials on Alzheimer's Disease (CTAD) 2023 annual conference held in Boston, Massachusetts, from October 24-27.
  • This novel mechanism of action makes Annovis' drug a potentially effective treatment option for AD and also for PD.
  • The posters' collective findings highlight a highly promising treatment for neurodegenerative conditions like Alzheimer's disease and Parkinson's disease.
  • Cheng Fang , Ph.D., senior vice president of research and development at Annovis Bio, is presenting two posters at CTAD.

Integra Connect to Present Key Clinical Research at the ASCO Quality Care Symposium

Retrieved on: 
Tuesday, October 24, 2023
NSCLC, American Society of Clinical Oncology, III, Biomarker, Water Quality Initiative, UPMC Hillman Cancer Center, Health, Research, AM, Society, Multimedia, Integra, Quality of life, PALM, Medicine, Histology, Abstract, HRR, Immunotherapy, Oncology, Lung cancer, Cancer, Patient, UPMC, ASCO, Nursing, Pharmaceutical industry, Stonemasonry, Medical imaging, MD

WEST PALM BEACH, Fla., Oct. 24, 2023 /PRNewswire/ -- Integra Connect, LLC., the leading provider of value-based, precision medicine solutions and services for specialty care, today announced results from three studies that will be presented during the 2023 American Society of Clinical Oncology (ASCO) Quality Care Symposium on October 27 - 28, 2023. The findings from these three studies – two done in conjunction with UPMC Hillman Cancer Center in Pittsburgh, PA and one done in conjunction with South Carolina Oncology Associates (SCOA) – emphasize the critical role quality initiatives play in identifying gaps in care and driving action to improve patient outcomes. Findings for all three posters will be presented at ASCO Quality Care Symposium from 7:00 - 8:00 AM ET, and then again from 11:45 AM - 1:00 PM ET on October 28, 2023.

Key Points: 
  • , the leading provider of value-based, precision medicine solutions and services for specialty care, today announced results from three studies that will be presented during the 2023 American Society of Clinical Oncology (ASCO) Quality Care Symposium on October 27 - 28, 2023.
  • Findings for all three posters will be presented at ASCO Quality Care Symposium from 7:00 - 8:00 AM ET, and then again from 11:45 AM - 1:00 PM ET on October 28, 2023.
  • The studies were conducted with Integra Connect as part of its Quality Initiatives program, which is designed to help oncology practices, cancer institutes, and health systems make well-informed clinical decisions to ensure patients are receiving the best possible care.
  • Integra Connect does this by bringing together clinical data from disparate systems and sources, organizing the information into complete, longitudinal patient journeys, and conducting in-depth analyses with its AI-enabled solutions.

Vixen Media Group Teamed Up with Artist Mokibaby on Dream Installation at III Points Festival in Miami

Retrieved on: 
Tuesday, October 24, 2023
White Knight, Element, III, Erotica, Stephanie Leigh Batiste, Life, News, Empowerment, Fox, Environment, White Limousine, Vixen Media Group, Music, Collection, VIP, Nightclub

LOS ANGELES, Oct. 24, 2023 /PRNewswire/ -- Vixen Media Group, the leader in luxury adult entertainment, announced a unique collaboration with Cuban American Artist Mokibaby (AKA Veronica Gessa) at the III Points 2023 festival in Miami on October 20-21. The global entertainment and lifestyle brand teamed with Mokibaby on a dream art installation featuring a Vixen-branded classic 1986 Lincoln St. Tropez White Limousine.

Key Points: 
  • The global entertainment and lifestyle brand teamed with Mokibaby on a dream art installation featuring a Vixen-branded classic 1986 Lincoln St. Tropez White Limousine.
  • The "White Knight" art installation represented one of many progressive pieces of the "Mokiworld" collection designed by Mokibaby, exclusively for III Points.
  • "We were absolutely thrilled to work with Mokibaby on this unique art piece at the III Points festival," said Stephanie Leigh, Creative Director at Vixen Media Group.
  • For more information about Vixen Media Group visit vixengroup.com , and be sure to follow Vixen on Instagram and X for the latest news on the brand's activation in Miami.

First Immunotherapy Success in TKI-Resistant Lung Cancer Setting Demonstrates Power of AI-driven Immune Phenotyping by Lunit SCOPE IO - newly published in JCO

Retrieved on: 
Tuesday, October 24, 2023
TKI, Bevacizumab, Patient, Pemetrexed, Arm, PC, NSCLC, Carboplatin, CDX, ESMO, Progression-free survival, III, Therapy, Lung cancer, Cisplatin, PFS, European Society for Medical Oncology, Phenotype, Research, TIL, JCO, Journal, Samsung Medical Center, ALK, Journal of Clinical Oncology, Annual general meeting, Immunotherapy, H&E, ORR, Oncology, ABCP, Mutation, EGFR, Pharmaceutical industry, Medical imaging

Against the backdrop of growing interest and need for an AI biomarker in medical practices, this marks the second time a study utilizing Lunit SCOPE IO has been published in the prestigious JCO.

Key Points: 
  • Against the backdrop of growing interest and need for an AI biomarker in medical practices, this marks the second time a study utilizing Lunit SCOPE IO has been published in the prestigious JCO.
  • Lunit SCOPE IO, an AI-powered TIL analyzer for assessing immune phenotype from H&E, played a pivotal role in this research.
  • Immune phenotype as assessed by Lunit SCOPE IO showed predictive power in stratifying patients more likely to respond to ABCP treatment.
  • "We aim for Lunit SCOPE IO to continue to make immune phenotyping a quantitative biomarker readily accessible for research, clinical use, and companion diagnostics (CDx) business."

Easterly Government Properties Acquires a 35,005 SF U.S. District Courthouse in Newport News, Virginia

Retrieved on: 
Monday, October 23, 2023
Professional Services, Other Construction & Property, Commercial Building & Real Estate, Finance, Construction & Property, REIT, Supreme court, LEED, Government, JV, Unitary state, NYSE, III, History, District Courthouse, United States magistrate judge, DEA, Acquisition, Law of the United Kingdom, Judiciary Act, Tenant, News, City, United States Marshals Service, Newport, Judiciary, District court, Women in the United States judiciary, JUD, Judiciary Act of 1789, United States district court, Court of cassation, Easterly, District Judge

Easterly Government Properties, Inc. (NYSE: DEA), a fully integrated real estate investment trust focused primarily on the acquisition, development and management of Class A commercial properties leased to the U.S. Government, announced today that it has acquired a 35,005 leased square foot United States District Courthouse in Newport News, Virginia (“JUD - Newport News”).

Key Points: 
  • Easterly Government Properties, Inc. (NYSE: DEA), a fully integrated real estate investment trust focused primarily on the acquisition, development and management of Class A commercial properties leased to the U.S. Government, announced today that it has acquired a 35,005 leased square foot United States District Courthouse in Newport News, Virginia (“JUD - Newport News”).
  • The United States District Court, Eastern District of Virginia, Newport News Division Courthouse is a highly specialized facility that features 2008 build-to-suit, LEED Certified construction, and a new 10-year firm term lease extension that does not expire until 2033.
  • JUD - Newport News houses four District Judges, three Senior District Judges, and three Magistrate Judges, and is responsible for the cities of Newport News, Hampton, and Williamsburg, and the counties of York, James City, Gloucester, and Matthews.
  • With this acquisition, Easterly owns, directly or through the JV, 90 properties totaling 8.9 million square feet.

5-Year Head & Neck Cancer Survival Increased From 45% to 73% in CEL-SCI’s Target Population, Cutting Risk of Death in Half, as Presented at Leading Cancer Conference ESMO 2023

Retrieved on: 
Monday, October 23, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Yale School of Medicine, Neoplasm, Patient, Survival, NYSE, ESMO, III, Life, Hope, Lymph, Physician, Congress, Head, European Society for Medical Oncology, Multimedia, Senior, Disease, Risk, Cis, Pembrolizumab, Immunotherapy, University, Consultant, LI, Cancer, Randomized controlled trial, PET-CT, Diagnosis, Death, Regulatory affairs, Pharmaceutical industry

CEL-SCI presented the data for the first time at the European Society for Medical Oncology (ESMO) Congress in Spain on October 22, 2023.

Key Points: 
  • CEL-SCI presented the data for the first time at the European Society for Medical Oncology (ESMO) Congress in Spain on October 22, 2023.
  • The target population is estimated to cover ~145,000 advanced primary head and neck cancer patients globally per year.
  • Second, the Multikine target population can now be readily identified upon diagnosis, prior to surgery, using tests that physicians routinely use in cancer screenings.
  • CEL-SCI is not aware of any head and neck cancer therapy that has shown such a large 5-year survival benefit.

First results from PEGASUS trial reported at ESMO show promise for use of liquid biopsy to guide adjuvant treatment of colon cancer

Retrieved on: 
Monday, October 23, 2023
Science, Other Science, Biometrics, Oncology, Health, Medical Devices, Genetics, Clinical Trials, Patient, Cohort (statistics), Liquid biopsy, III, Congress, MD, Doctor of Philosophy, Circulating tumor DNA, Helmy Eltoukhy, PEGASUS, GH, Biology, Recurrence, MRD, Cancer, ISS, Toxicity, Neoplasm, Rollcage Stage II, DNA, Pharmaceutical industry, Medical imaging

One of the first prospective studies using liquid biopsy, the PEGASUS trial includes 135 patients recruited from 11 cancer centers in Italy and Spain.

Key Points: 
  • One of the first prospective studies using liquid biopsy, the PEGASUS trial includes 135 patients recruited from 11 cancer centers in Italy and Spain.
  • Initial results show that 34% of patients with a positive liquid biopsy result after surgery had the cancer return, while only 10% of patients with a negative result experienced a relapse.
  • Approximately 40% of patients converted from ctDNA-positive to ctDNA-negative after treatment, suggesting treatment efficacy of chemotherapy for some patients.
  • “A shift from the current paradigm of one-size-fits-all chemotherapy toward a new paradigm of tailored therapies is not the only expected impact of the PEGASUS trial.

Celltrion USA Announces U.S. FDA Approval of ZYMFENTRA® (infliximab-dyyb), the First and Only Subcutaneous infliximab, for the Treatment of People With Inflammatory Bowel Disease

Retrieved on: 
Monday, October 23, 2023
FDA, Health, Other Health, Clinical Trials, Pharmaceutical, Biotechnology, Patent, Food, Biologics license application, III, UC, Infliximab, Public Health Service Act, Celltrion, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Maintenance, Ulcerative colitis, Mount Sinai, Cedars-Sinai Medical Center, IBD, Safety, Patient, CD, BLA, United States Public Health Service, Icahn School of Medicine at Mount Sinai, Pharmaceutical industry, Medicine

Based on the results of the LIBERTY UC and LIBERTY CD studies, ZYMFENTRA demonstrated superiority in the primary endpoints of clinical remission (UC and CD) and endoscopic response (CD) compared to placebo as maintenance therapy after induction therapy of intravenous formulation of infliximab in patients with UC and CD, over a 54-week study period.

Key Points: 
  • Based on the results of the LIBERTY UC and LIBERTY CD studies, ZYMFENTRA demonstrated superiority in the primary endpoints of clinical remission (UC and CD) and endoscopic response (CD) compared to placebo as maintenance therapy after induction therapy of intravenous formulation of infliximab in patients with UC and CD, over a 54-week study period.
  • The overall safety profile of ZYMFENTRA was similar to that of placebo during maintenance period in both studies with no new safety signals seen.2,3
    “There remains an unmet need for patients who suffer from the day-to-day burden of living with moderately to severely active Crohn’s disease and ulcerative colitis,” said Thomas Nusbickel, Chief Commercial Officer at Celltrion USA.
  • “As someone dedicated to improving the lives of patients with IBD, I am excited to see data supporting the efficacy and safety of a new formulation offering convenience and improved access to a well-known and proven drug,” said Dr. Andres Yarur of Cedars-Sinai Medical Center.
  • ZYMFENTRA will be under patent protection by 2037 for its dosage form and route of administration by 2040.

United States Clinical Trials Support Services Markets, 2023-2028 with Charles River Laboratories, IQVIA, Icon, Labcorp Drug Development, and Syneos Health Dominating - ResearchAndMarkets.com

Retrieved on: 
Friday, October 20, 2023
Health, Clinical Trials, Incidence, III, Syneos Health, Charles River Laboratories, ICON PLC, II, Prevalence, Conditional sentence, Research, Phase, Growth, Clinical trial, Labcorp Drug Development, Cancer, Patient, Pharmaceutical industry

The "US Clinical Trials Support Services Market - Focused Insights 2023-2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "US Clinical Trials Support Services Market - Focused Insights 2023-2028" report has been added to ResearchAndMarkets.com's offering.
  • The demand for clinical trial support services is witnessing a significant upswing, driven by various factors such as a surge in research and development activities, a high prevalence of chronic diseases, and the increasing adoption of clinical trial support services.
  • Prominent companies dominating the US clinical trial support services market include Charles River Laboratories, IQVIA Inc, Icon plc, Labcorp Drug Development, and Syneos Health.
  • The report offers an in-depth analysis of the current market dynamics for the US clinical trial support services market from 2023 to 2028.

Personalis Announces Late-Breaking NeXT Personal Abstract and Proffered Paper Presentation at ESMO 2023

Retrieved on: 
Thursday, October 19, 2023
Biotechnology, Health, Genetics, Health Technology, Oncology, Congress, PSNL, Research, NeXT, European Society for Medical Oncology, Neoplasm, ESMO, Abstract, III, Medical imaging, Pharmaceutical industry

Personalis, Inc .

Key Points: 
  • Personalis, Inc .
  • (Nasdaq: PSNL), a leader in precision oncology, today announced that a late-breaking abstract featuring data for the company’s NeXT Personal® whole genome-based, tumor-informed assay for ultra-sensitive ctDNA detection, has been accepted and selected for a proffered paper presentation at the 2023 European Society for Medical Oncology (ESMO) Congress, on October 21 in Madrid, Spain.
  • Late-breaking abstracts are typically reserved for high-quality, new research findings from randomized phase II or phase III trials with implications for clinical practice or understanding of disease processes.
  • Proffered papers are oral presentations of original data of superior quality, followed by expert discussion and perspectives.